Author Affiliation: Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles.
Downing et al1 present the opinion that Abbott's various brands of fenofibrate and fenofibric acid inappropriately manipulated the patent and drug approval process to protect brand profits. However, it is likely that Abbott would have provided substantial confidential rebates and discounts for its various branded fenofibrate products to maintain favorable formulary status and market share. Absent this and other confidential trial document information, it is impossible to know if and how much consumers were actually harmed by Abbott's alleged behavior.
Hay JW. What Is More Valuable: Fenofibrate Patents or Fenofibrate Clinical Outcomes? Arch Intern Med. 2012;172(19):1521–1522. doi:10.1001/archinternmed.2012.4386
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: